Fibrotic Burden in Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes

Author(s)
임태섭
Advisor
정재연
Department
일반대학원 의학과
Publisher
The Graduate School, Ajou University
Publication Year
2022-08
Language
eng
Keyword
Metabolic dysfunction-associated fatty liver diseaseliver fibrosisnon-alcoholic fatty liver diseasesubtype
Abstract
배경 및 목적: 대사이상관련 지방간질환 (metabolic dysfunction-associated fatty liver disease, 이하 MAFLD)은 세개의 아형으로 분류된다: 과체중/비만 (overweight/obesity, 이하 OW), 대사이상을 동반한 정상체중 (이하 lean), 당뇨 (diabetes mellitus, 이하 DM). 우리는 MAFLD아형에 따라 간 섬유화의 정도가 다른 지 여부를 조사하였다. 방법: 이 횡단면 다기관 연구는 2014년 1월부터 2020년 12월 사이에 종합 건강 검진을 받은 코호트를 기반으로 하였다. 초음파로 진단된 지방간이 있는 총 42,652명의 환자가 본 연구에 포함되었다. 환자들은 no MAFLD, OW-MAFLD, lean-MAFLD, DM-MAFLD로 분류되었다. 진행된 간 섬유화는 non-alcoholic fatty liver disease fibrosis score (이하 NFS) 또는 fibrosis-4 (이하 FIB-4) index를 기반으로 정의하였다. 결과: 환자의 평균연령은 50.0세였고, 남자가 74.1%였다. NFS로 정의된 진행된 간 섬유화가 있는 환자의 비율은 DM-MAFLD (6.6%)에서 가장 높았고, OW-MAFLD (2.0%), lean-MALFD (1.3%), no MALFD (0.2%)가 그 뒤를 이었다. FIB-4로 정의된 진행된 간 섬유화가 있는 환자의 비율은 DM-MAFLD (8.6%)에서 가장 높았고, 그 다음이 lean-MAFLD (3.9%), OW-MAFLD (3.0%), no MAFLD (2.0%)의 순서였다. “no MAFLD”그룹을 참조로 하여 NFS로 정의된 진행된 간 섬유화에 대한 adjusted odds ratios (95% 신뢰구간)는 OW-MAFLD, lean-MAFLD, DM-MAFLD에서 각각 4.46 (2.09–9.51), 2.81 (1.12–6.39), 9.52 (4.46–20.36) 였고, FIB-4로 정의된 진행된 간 섬유화의 adjusted odds ratios (95% 신뢰구간)는 OW-MAFLD, lean-MAFLD, DM-MAFLS에서 각각 1.03 (0.78–1.36), 1.14 (0.82–1.57), and 1.97 (1.48–2.62)였다. 결론: 간 섬유화의 정도는 MAFLD의 아형에 따라 다르다. 따라서, 각각의 MAFLD 하위 유형에 따른 최적화된 감시 전략 및 치료 선택이 필요할 수 있다.
Alternative Abstract
Background & Aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) is categorized into three subtypes: overweight/obese (OW), lean/normal weight with metabolic abnormalities, and diabetes mellitus (DM). We investigated whether fibrotic burden in liver differs across subtypes of MAFLD patients. Methods: This cross-sectional multicenter study was based on cohorts of patients who underwent a comprehensive medical health checkup between January 2014 and December 2020. A total of 42,652 patients with ultrasound-diagnosed fatty liver were included. Patients were classified as no MAFLD, OW-MAFLD, lean-MAFLD, and DM-MAFLD. Advanced liver fibrosis was defined based on the non-alcoholic fatty liver disease fibrosis score (NFS) or fibrosis-4 (FIB-4) index. Results: The mean age of the patients was 50.0 years, and 74.1% were male. The proportion of patients with NFS-defined advanced liver fibrosis was the highest in DM-MAFLD (6.6%), followed by OW-MAFLD (2.0%), lean-MAFLD (1.3%), and no MAFLD (0.2%). The proportion of patients with FIB-4-defined advanced liver fibrosis was the highest in DM-MAFLD (8.6%), followed by lean-MAFLD (3.9%), OW-MAFLD (3.0%), and no MAFLD (2.0%). With the “no MAFLD” group as reference, the adjusted odds ratios (95% confidence intervals) for NFS-defined advanced liver fibrosis were 4.46 (2.09–9.51), 2.81 (1.12–6.39), and 9.52 (4.46–20.36) in OW-MAFLD, lean-MAFLD, and DM-MAFLD, respectively, and the adjusted odds ratios for FIB-4-defined advanced liver fibrosis were 1.03 (0.78–1.36), 1.14 (0.82–1.57), and 1.97 (1.48–2.62) in OW-MAFLD, lean-MAFLD, and DM-MAFLD, respectively. Conclusions: Fibrotic burden in liver differs across MAFLD subtypes. Optimized surveillance strategies and therapeutic options might be needed for different MAFLD subtypes.
URI
https://dspace.ajou.ac.kr/handle/2018.oak/20774
Fulltext

Appears in Collections:
Graduate School of Ajou University > Department of Medicine > 4. Theses(Ph.D)
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse